Now, the breakthrough advance is the programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) monoclonal antibody, which is used in first-line immune checkpoint inhibitors (ICIs) in lung cancer (3–5). Here, CD274 is linked to lung carcinoma.